Sugimoto M - Search Results

1

Randomised trial of acid inhibition by vonoprazan 10/20 mg once daily vs rabeprazole 10/20 mg twice daily in healthy Japanese volunteers (SAMURAI pH study).

Takeuchi T, Furuta T, Fujiwara Y, Sugimoto M, Kasugai K, Kusano M, Okada H, Suzuki T, Higuchi T, Kagami T, Uotani T, Yamade M, Sawada A, Tanaka F, Harada S, Ota K, Kojima Y, Murata M, Tamura Y, Funaki Y, Kawamura O, Okamoto Y, Fujimoto K, Higuchi K. Takeuchi T, et al. Among authors: sugimoto m. Aliment Pharmacol Ther. 2020 Mar;51(5):534-543. doi: 10.1111/apt.15641. Epub 2020 Jan 28. Aliment Pharmacol Ther. 2020. PMID: 31990424 Clinical Trial.

2

Retreatment of H. pylori with dual therapy using high doses of rabeprazole or lansoprazole can be effective.

Furuta T, Shirai N, Sugimoto M, Ohashi K, Ishizaki T. Furuta T, et al. Among authors: sugimoto m. Aliment Pharmacol Ther. 2003 Dec;18(11-12):1175-6. doi: 10.1046/j.1365-2036.2003.01765.x. Aliment Pharmacol Ther. 2003. PMID: 14653841 No abstract available.

3

High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin.

Furuta T, Shirai N, Xiao F, Takashita M, Sugimoto M, Kajimura M, Ohashi K, Ishizaki T. Furuta T, et al. Among authors: sugimoto m. Hepatogastroenterology. 2003 Nov-Dec;50(54):2274-8. Hepatogastroenterology. 2003. PMID: 14696516 Clinical Trial.

4

Pharmacogenomics of proton pump inhibitors.

Furuta T, Shirai N, Sugimoto M, Ohashi K, Ishizaki T. Furuta T, et al. Among authors: sugimoto m. Pharmacogenomics. 2004 Mar;5(2):181-202. doi: 10.1517/phgs.5.2.181.27483. Pharmacogenomics. 2004. PMID: 15016609 Review.

5

Controversy in polymorphisms of interleukin-1beta in gastric cancer risks.

Furuta T, Shirai N, Sugimoto M. Furuta T, et al. Among authors: sugimoto m. J Gastroenterol. 2004;39(5):501-3. doi: 10.1007/s00535-004-1353-6. J Gastroenterol. 2004. PMID: 15175954 No abstract available.

6

Different dosage regimens of rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotype status.

Sugimoto M, Furuta T, Shirai N, Kajimura M, Hishida A, Sakurai M, Ohashi K, Ishizaki T. Sugimoto M, et al. Clin Pharmacol Ther. 2004 Oct;76(4):290-301. doi: 10.1016/j.clpt.2004.06.008. Clin Pharmacol Ther. 2004. PMID: 15470328 Clinical Trial.

7

Concomitant dosing of famotidine with a triple therapy increases the cure rates of Helicobacter pylori infections in patients with the homozygous extensive metabolizer genotype of CYP2C19.

Okudaira K, Furuta T, Shirai N, Sugimoto M, Miura S. Okudaira K, et al. Among authors: sugimoto m. Aliment Pharmacol Ther. 2005 Feb 15;21(4):491-7. doi: 10.1111/j.1365-2036.2005.02353.x. Aliment Pharmacol Ther. 2005. PMID: 15710002 Clinical Trial.

8

Comparison of an increased dosage regimen of rabeprazole versus a concomitant dosage regimen of famotidine with rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotypes.

Sugimoto M, Furuta T, Shirai N, Nakamura A, Kajimura M, Hishida A, Ohashi K, Ishizaki T. Sugimoto M, et al. Clin Pharmacol Ther. 2005 Apr;77(4):302-11. doi: 10.1016/j.clpt.2004.10.010. Clin Pharmacol Ther. 2005. PMID: 15903128 Clinical Trial.

9

Influence of CYP2C19 polymorphism and Helicobacter pylori genotype determined from gastric tissue samples on response to triple therapy for H pylori infection.

Furuta T, Sagehashi Y, Shirai N, Sugimoto M, Nakamura A, Kodaira M, Kenmotsu K, Nagano M, Egashira T, Ueda K, Yoneyama M, Ohashi K, Ishizaki T, Hishida A. Furuta T, et al. Among authors: sugimoto m. Clin Gastroenterol Hepatol. 2005 Jun;3(6):564-73. doi: 10.1016/s1542-3565(04)00779-7. Clin Gastroenterol Hepatol. 2005. PMID: 15952098

10

Effect of concomitant dosing of famotidine with lansoprazole on gastric acid secretion in relation to CYP2C19 genotype status.

Furuta T, Shirai N, Sugimoto M, Nakamura A, Okudaira K, Kajimura M, Hishida A. Furuta T, et al. Among authors: sugimoto m. Aliment Pharmacol Ther. 2005 Jul 1;22(1):67-74. doi: 10.1111/j.1365-2036.2005.02523.x. Aliment Pharmacol Ther. 2005. PMID: 15963082 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,382 results

Search Page

Filters